📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. (2024)

First Author: Myint KZ

Attributed to: Role of heparin binding growth factors in O.viverrini induced Cholangiocarcinoma (O-CCA) development, progression and angiogenesis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/ph17020197

PubMed Identifier: 38399413

Publication URI: http://europepmc.org/abstract/MED/38399413

Type: Journal Article/Review

Volume: 17

Parent Publication: Pharmaceuticals (Basel, Switzerland)

Issue: 2

ISSN: 1424-8247